Form 4: Guardant Health Director Sells Shares Under 10b5-1 Plan

Guardant Health Director Tariq Musa sold 116 shares of common stock for $66.95 per share on October 17, 2025, under a pre-arranged Rule 10b5-1 plan.

Summary

• Tariq Musa, a Director of Guardant Health, Inc. (GH), reported a transaction involving the company's common stock.
• The transaction occurred on October 17, 2025, and was a sale of 116 shares.
• Each share was sold at a price of $66.95.
• The sale was executed pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Tariq Musa beneficially owns 7,725 shares of Guardant Health common stock directly.

Sentiment

Score: 5

Explanation: A routine insider stock sale under a pre-arranged 10b5-1 plan, which typically does not indicate a strong positive or negative sentiment regarding the company's prospects.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate, non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• An insider sale, even if pre-planned, results in a reduction of the director's direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• The sale of 116 shares of common stock by Director Tariq Musa is a related party transaction, as reported on this Form 4.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in a director's direct equity holding, which is generally not expected to have a significant impact on shareholder value given the small volume and pre-planned nature.

Key Dates

Recommendation

The filing reports a routine, pre-scheduled sale of a small number of shares by a director under a 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a strong signal for investors to alter their positions. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Guardant Health, GH, Tariq Musa, Director, Insider Sale, Form 4, 10b5-1 Plan, Stock Transaction